Development of in vivo simultaneous drug monitoring system

2022 Fiscal Year Final Research Report

• Project/Area Number: 20K16005
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 47040:Pharmacology-related
• Research Institution: Osaka University (2021-2022); Niigata University (2020)
• Principal Investigator: Seishiro Sawamura 大阪大学, 大学院医学系研究科, 招へい教員 (10781974)
• Project Period (FY): 2020-04-01 – 2023-03-31
• Keywords: 抗てんかん薬 / 電気化学 / 生体計測

Outline of Final Research Achievements

For the treatment of refractory epilepsy, multiple antiepileptic drugs would be administered. However, by conventional analytical methods, it is difficult to quantitatively evaluate pharmacokinetics and cellular functions. Therefore, limited knowledge regarding the combined effects of these drugs is available. In this study, we developed a drug monitoring system using a "needle-like diamond sensor" and created a measurement method to quantitatively and simultaneously monitor multiple antiepileptic drugs in vivo with high sensitivity and real-time capability. This technique is expected to contribute to the quantitative understanding of drug-drug interactions in polytherapy.

Free Research Field

薬理学

Academic Significance and Societal Importance of the Research Achievements

てんかん症例の約3割は単一薬治療に抵抗性の難治性てんかんだとされる。これに対して多剤併用治療が標準的に実施されるが、効果的な組み合わせの予測は難しく、治療効果が少ないことや副作用の発現に苦しむ患者も多い。本研究で創出した、抗てんかん薬の新規計測法は、in vivoリアルタイムでの感度および分解能の高い薬物濃度計測を可能にする。これによって得られる知見は、従来法では難しい、複数薬の相互作用の定量的理解を進めることに貢献する。